FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	DC	20549
vvasilington,	D.O.	20070

<b>STATEMENT</b>	<b>OF CHANGES</b>	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response	. 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     KAKKIS EMIL D				2. Issuer Name and Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [ RARE ]							5. Relationship (Check all app X Direct		licable) tor	10%	Owner			
	(Fir TRAGENY) ERONI COU	X PHARMACE	Middle) UTIC	AL INC.	01/04/2021				nsaction (Month/Day/Year)					X	below	Presiden	Other (specify below)  nt & CEO	
(Street) NOVATO	) CA	Λ 9	4949		4. If <i>i</i>	Amend	ment, Date	of Ori	gina	l File	ed (Month/Day	y/Year)		6. Indiv Line)	Form	filed by One	o Filing (Checo e Reporting P re than One R	erson
(City)	(Sta	ate) (Z	Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date			2. Transacti Date (Month/Day	y/Year)   Execut		eemed ition Date, h/Day/Year)		Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		4 and 5) Securi Benefi Owner		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect		
								Cod	e \	v	Amount	nt (A) or Pric			Reported Transaction(s) (Instr. 3 and 4)			(ilisti. 4)
Common Stock 0			01/04/20	2021			S <sup>(1)</sup>			30,000	D	\$1	\$136.9 <sup>(2)</sup>		2,329,741		By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009	
Common	Stock														610	),189 <sup>(3)</sup>	D	
		Tal	ble II -							•	osed of, o			-	Owne	d		
1. Title of 2. 3. Transaction 3A. Deemed Execution Date, or Exercise (Month/Day/Year)				4. Transa	I. 5. Number of Code (Instr. Deriv.		6. Date Exerc Expiration D (Month/Day/			cisable and ate	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		8. P Der Sec (Ins	Perivative	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership ct (Instr. 4)	
					Code	v	(A) (D)	Date Exe		able	Expiration Date	Title	Amou or Numb of Share	er				

## Explanation of Responses:

- 1. The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$135.66 to \$138.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price
- 3. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

## Remarks:

/s/ Karah Parschauer, attorney-01/05/2021 in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.